{"nctId":"NCT01318070","briefTitle":"Efficacy and Safety of Alogliptin Used Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan","startDateStruct":{"date":"2007-11"},"conditions":["Type 2 Diabetes Mellitus"],"count":339,"armGroups":[{"label":"Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Alogliptin and pioglitazone"]},{"label":"Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Alogliptin and pioglitazone"]},{"label":"Pioglitazone (15mg or 30mg ) QD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pioglitazone"]}],"interventions":[{"name":"Alogliptin and pioglitazone","otherNames":["Alogliptin (SYR-322)","Pioglitazone: Actos®"]},{"name":"Alogliptin and pioglitazone","otherNames":["Alogliptin (SYR-322)","Pioglitazone: Actos®"]},{"name":"Pioglitazone","otherNames":["Pioglitazone: Actos®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Had been taking pioglitazone at a stable dose (15 mg/day or 30 mg/day) for at least 16 weeks prior to the start of the treatment period (Week 0).\n2. Had glycosylated hemoglobin (HbA1c) of 6.5% or more and below 10.0% at 14 weeks after the start of the observation period (Week -2).\n3. Had HbA1c difference within 10.0%\\* at 10 weeks after the start of the observation period (Week -6) and 14 weeks after the start of the observation period (Week -2) from 10 weeks after the start of the observation period (Week -6) (\\*rounded off to the first decimal place).\n4. Was receiving specific diet and exercise (if any) therapies during the observation period.\n\nExclusion Criteria:\n\n1. Had taken a diabetic medications other than pioglitazone within 16 weeks before the start of the treatment period (Week 0).\n2. Had a history or symptoms of cardiac failure.","healthyVolunteers":false,"sex":"ALL","minimumAge":"33 Years","maximumAge":"88 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change From Baseline in Glycosylated Hemoglobin (Week 2).","description":"The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"0.150"},{"groupId":"OG001","value":"-0.22","spread":"0.154"},{"groupId":"OG002","value":"-0.04","spread":"0.186"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycosylated Hemoglobin (Week 4).","description":"The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.47","spread":"0.236"},{"groupId":"OG001","value":"-0.46","spread":"0.254"},{"groupId":"OG002","value":"-0.10","spread":"0.301"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycosylated Hemoglobin (Week 8).","description":"The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.76","spread":"0.353"},{"groupId":"OG001","value":"-0.81","spread":"0.398"},{"groupId":"OG002","value":"-0.17","spread":"0.433"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (Week 2).","description":"The change between the value of fasting plasma glucose collected at week 2 and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.8","spread":"14.68"},{"groupId":"OG001","value":"-17.0","spread":"18.36"},{"groupId":"OG002","value":"-3.9","spread":"18.25"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (Week 4).","description":"The change between the value of fasting plasma glucose collected at week 4 and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.4","spread":"18.45"},{"groupId":"OG001","value":"-17.9","spread":"20.16"},{"groupId":"OG002","value":"-3.1","spread":"19.54"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (Week 8).","description":"The change between the value of fasting plasma glucose collected at week 8 and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.1","spread":"16.96"},{"groupId":"OG001","value":"-21.3","spread":"20.20"},{"groupId":"OG002","value":"-4.2","spread":"22.29"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (Week 12).","description":"The change between the value of fasting plasma glucose collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.9","spread":"18.42"},{"groupId":"OG001","value":"-18.9","spread":"20.96"},{"groupId":"OG002","value":"-2.4","spread":"26.84"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Blood Glucose Measured by the Meal Tolerance Test (Week 12).","description":"The change between the value of blood glucose measured by the meal tolerance test collected at week 12 or final visit and blood glucose measured by the meal tolerance test collected at baseline. Meal tolerance test measures blood glucose through blood samples drawn before a meal and 2 hours after the start of the meal.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":"28.75"},{"groupId":"OG001","value":"49.4","spread":"29.27"},{"groupId":"OG002","value":"70.6","spread":"39.58"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Glycosylated Hemoglobin (Week 12).","description":"The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.91","spread":"0.441"},{"groupId":"OG001","value":"-0.97","spread":"0.517"},{"groupId":"OG002","value":"-0.19","spread":"0.552"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":111},"commonTop":["Nasopharyngitis","Blood creatine phosphokinase increased","Dental caries"]}}}